{"disease":{"id":"diagnostic-test-for-primary-aldosteronism","name":"Diagnostic Test for Primary Aldosteronism","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"spironolacton","indication_name":"Diagnostic Test for Primary Aldosteronism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Spironolacton","company_name":"ACS Biomarker","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"spironolactone","indication_name":"Diagnostic Test for Primary Aldosteronism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"spironolactone","company_name":"Generic (originally Searle/Pfizer)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"Aldosterone Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Potassium-sparing diuretic and mineralocorticoid receptor antagonist that blocks aldosterone, reducing fluid retention and lowering blood pressure."},{"drug_id":"spirolactone","indication_name":"Diagnostic Test for Primary Aldosteronism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"spirolactone","company_name":"Second Xiangya Hospital of Central South University","drug_phase":"phase_1","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}